Hehlmann, R., Müller, M. C., Lauseker, Michael, Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, Markus, Haferlach, C., Schnittger, S., Einsele, H., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, Karsten, Baerlocher, Gabriela M., Ehninger, G., Heim, D., Heimpel, H., Nerl, C., Krause, S. W., Hossfeld, D. K., Kolb, H. J., Hasford, Joerg, Saußele, Susanne and Hochhaus, A.
(2014):
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV.
In: Journal of Clinical Oncology, Vol. 32, No. 5: pp. 415-423
Full text not available from 'Open Access LMU'.
Actions (login required)
- View Item
